Peripheral primitive neuroectodermal tumors (pPNETs) are small embryonic carcinomas that develop in the soft tissue and bone, away from the central nervous system (CNS) and sympathetic nervous system ...
Dr. Kimberly Perez and Dr. Jaydira Del Rivero discuss the new guideline from ASCO on symptom management for well-differentiated GEP-NETs. They share the latest recommendations on managing symptoms ...
MIAMI, FLORIDA (April 30, 2024) – Newly updated guidelines on neuroendocrine tumors developed by an expert at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine ...
The US Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx, Exelixis, Inc.) for certain adults and children aged ≥ 12 years with previously treated, well-differentiated pancreatic ...
Everyday health complaints like fatigue, stomach pain or flushing may seem harmless - but for some Australians, they could point to a far more ...
Based on the phase 3 CABINET trial, the FDA approved Cabometyx for some patients with previously treated neuroendocrine tumors. The U.S. Food and Drug Administration (FDA) has approved Cabometyx ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results